EpiBiologics Advances Degraders of Membrane-Bound Proteins

EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit. EpiTAC bispecific antibodies leverage cell-surface degrader receptors enriched in disease tissue to selectively degrade membrane and extracellular targets and address significant unmet needs.

"We believe EpiTACs are a promising new modality, especially for difficult-to-drug targets,” said Ann Lee-Karlon, Ph.D., President and CEO of EpiBiologics. "We’re committed to advancing EpiTACs for diverse targets in oncology and other disease areas."

Congratulations to everyone at the Wells lab, especially Jim Wells! 

Article

Press Release